Smith & Nephew Spray-On Wound Therapy Misses Leg Ulcer Endpoint
This article was originally published in The Gray Sheet
A phase III study of the firm's live cell spray-on wound therapy (HP802-247) failed, putting the future of the product, acquired by Smith & Nephew in 2012, in question.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.